Form 8-K - Current report:
SEC Accession No. 0001420720-24-000053
Filing Date
2024-11-12
Accepted
2024-11-12 16:06:21
Documents
15
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20240930x8k.htm   iXBRL 8-K 31861
2 EX-99.1 ibio-20240930xex99d1.htm EX-99.1 15652
  Complete submission text file 0001420720-24-000053.txt   178369

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20240930.xsd EX-101.SCH 4162
4 EX-101.DEF ibio-20240930_def.xml EX-101.DEF 3993
5 EX-101.LAB ibio-20240930_lab.xml EX-101.LAB 14534
6 EX-101.PRE ibio-20240930_pre.xml EX-101.PRE 10733
18 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20240930x8k_htm.xml XML 4873
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 241448027
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)